Dear Editor, Thrombotic thrombocytopenic purpura (TTP) is a rare complication of pregnancy with a poor prognosis and a high fetal mortality when presenting early during gestation. Few cases of TTP (10%) occur during the first trimester [1, 2] , the majority occurring at the time of delivery or during post-partum period [4, 6] . Until the effectiveness of plasma infusion and plasma exchange was recognized, TTP was associated with a mortality rate of 95% and, in case of pregnancy-related TTP, the maternal survival was rare and the fetal mortality rate approached 80% [9] . Fetal death is secondary to placental infarction due to thrombotic occlusion of the decidual arterioles [8] . Currently, plasma infusion and plasmapheresis have improved maternal and fetal survival rates [10] . At present, it is well known that termination of pregnancy is rarely needed and that the fetal survival rate could be improved by effective maternal therapy [14] . When TTP occurs during the first trimester of pregnancy and delivery of a viable infant is not an option, plasma exchange treatment is urgently indicated and may allow the pregnancy to continue [13] . There are some reports showing that prolonged courses of plasma exchange, beginning as early as 6 weeks of gestation, may achieve and maintain a remission of TTP allowing delivery of a healthy, full-term infant [1] . When plasma exchange fails to induce remission, therapeutic abortion may be considered, although the response of TTP to termination of pregnancy is uncertain. We have previously reported a case of a successful pregnancy in a young female who developed a severe TTP relapse at 18 weeks of gestation [5] . In the present study, we describe a case of a first pregnancy concomitant to a severe TTP diagnosed in the first trimester with maternal survival and delivery of a healthy child.
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In August 2004, a 26-year-old nulliparous woman at 9 weeks of gestation presenting macrohematuria and ecchymoses was admitted to our institution. Laboratory data showed thrombotic microangiopathy, with anemia (7.5 g/dl), thrombocytopenia (platelets 6×10 9 /l), numerous schistocytes (60%) in the peripheral blood smears, elevated levels of lactic dehydrogenase (1,472 IU/l range 70-190) and bilirubin (total 3.4 mg/dl, normal value 0.4-1.1, indirect 3 mg/dl, normal value 0.1-0.4), reticulocytosis (250×10 9 /l), and negative direct/indirect Coombs' test. Renal function was normal. Bone marrow aspirate showed a normal bone marrow cytomorphology. Thrombophilic screening showed normal levels of antithrombin (AT), absence of lupus anticoagulant (LAC), normal levels of C and S proteins, and no mutations of Leiden Factor V and prothrombin gene, while a heterozygous mutation of MTHFR C677T, with normal plasma homocysteine concentrations, was found. Serologic examinations were negative for anti-extractable nuclear antibodies and anticardiolipin antibodies. Unfortunately, ADAMTS-13 levels and inhibitor were not determined during the acute event.
On the basis of the symptoms and laboratory tests, a clinical diagnosis of TTP was made and the patient was treated with intravenous methylprednisolone (2 mg/kg/die to 120 mg/die) and daily plasmapheresis, with plasma replacement of 30 ml/kg/die, in combination with continuous infusion of fresh frozen plasma (FFP) (10 ml/kg/die). Folic acid (15 mg/die) support was given. The initial response was good: after five daily plasma exchanges, the peripheral blood smears showed a decrease in schistocyte count and the platelet count rose to 105×10 9 /l; on day 6, prophylactic treatment with low-dose aspirin was started (100 mg/die) together with the infusion of FFP and daily plasmapheresis. On day 11, the laboratory evaluation showed a decrease of platelet count (platelets 46×10 9 /l) and anemia (7.6 g/dl), with an increase of schistocytosis on peripheral blood smear and reticulocytosis. Aspirin was discontinued and the patient was treated with two doses of intravenous immunoglobulins (800 mg/kg/die, days 11 and 16). Plasma exchange was carried out every day. Response to treatment was observed 4 days after the second dose of immunoglobulins, with a decrease in schistocyte count and a progressive increase of the platelets until normalization (more than 150×10 9 /l) on day 24. After complete and stable recovery of the platelets, the doses of steroids were gradually reduced to 1 mg/kg/die, plasma infusion was discontinued, and plasmapheresis was performed every other day for 2 weeks, then twice weekly for 1 week. After discharge, the patient was submitted to weekly plasma exchange for 1 month, then every 2 weeks until delivery. Methylprednisolone treatment was gradually tapered until 8 mg/die. During hospitalization and subsequently the ultrasonographic examination showed a fetal biometry with harmonious growth. At 35 weeks, the patient had spontaneous contractions and delivered a 2,000 g healthy male baby (Apgar score 9 after 1 min and 10 after 5 min) by cesarean section after epidural analgesia. As prophylactic treatment of venous thromboembolism, low molecular weight heparin (enoxaparin 2,000 IU sc/die) was started after delivery and prolonged for 6 weeks. Prophylactic treatment with dipyridamole was started 2 weeks after cesarean section [3, 5] . Steroids were discontinued 10 months after delivery. The patient is in continuous complete remission from TTP 38 months later under prophylactic treatment with dipyridamole. ADAMTS-13 activity is normal.
Despite our successful experience, the issue of optimal management of TTP during pregnancy remains unresolved, especially when it occurs in the first trimester. Very few cases are described in the literature and the disease causes are not known. Some studies have shown that pregnancy may be a risk factor for acute episodes of TTP because of the association of pregnancy with increasing concentrations of procoagulant factors, decreasing fibrinolytic activity, loss of endothelial cell thrombomodulin, and decreasing activity of ADAMTS-13 [6, 7] . All of these abnormalities become progressively more severe through the course of pregnancy until delivery and immediately post-partum; in fact, the majority of cases occurred at this time.
According to the guidelines of the British Committee for Standards in Haematology [14] , pregnant patients should be treated with plasma exchange as non-pregnant patients and delivery is recommended only for those women who do not respond to plasmapheresis. Plasma exchange should be continued for several days after normalization of platelets count and resolution of hemolysis is documented [3] [4] [5] 9] . It has now been demonstrated that pregnancy does not impair the response to plasmapheresis and that plasmapheresis does not impair the outcome of pregnancy [3, 4] . Monitoring ADAMTS-13 activity may guide the intensity of therapy, but plasma-responsive TTP may occur in the absence of an overt deficiency of ADAMTS-13. There is considerable evidence that TTP is an immune-mediated disease, due to the presence of both anti-platelet and antiendothelial cell antibodies and inhibitors to the ADAMTS-13 [10] . Therefore, it is appropriate to include intravenous immunoglobulin G therapy and glucocorticoids, as prednisone and methylprednisolone, because they do not cross the placenta [3, 4] in the management of TTP [10, 11] . An issue specific for young women is the risk for future pregnancies. Several authors indicate that TTP has an overall relapse rate of 30-60% and pregnancy may precipitate relapse in women with a history of TTP unrelated to pregnancy; however, the real risk for relapse associated with this condition has not been well documented [5, [8] [9] . Women whose initial episode of TTP was idiopathic appear to have a greater risk of recurrence during a subsequent pregnancy compared to women whose initial episode was associated with a pregnancy [12] . With careful counseling and shared assessment of potential risks by the patient and her physicians, and with careful prenatal management, a future pregnancy may be a safe and acceptable decision. These pregnancies should be managed in a care unit where plasmapheresis is available without delaying in the plasma therapy.
